MedTrace Logo

Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients

NCT02933736 · Status: ACTIVE_NOT_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2026-03-06

No results posted yet for this study

Summary

In the proposed trial, patients will be administered ribociclib prior to surgical resection of their tumor. Patients will be enrolled in time-intervals sequentially (non-randomized). All patients will be orally-administered 5 doses of LEE011 (900 mg/d) with the final dose occurring at one of 3 intervals before brain tumor resection.

Conditions

Interventions

DRUG

Ribociclib

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Ivy Brain Tumor Center

    collaborator OTHER

  • Barrow Neurological Institute

    collaborator OTHER

  • Nader Sanai

    lead OTHER

Principal Investigators

  • Nader Sanai, MD · Deputy Director of the Ivy Brain Tumor Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-17
Primary Completion
2023-03-01
Completion
2027-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02933736 on ClinicalTrials.gov